NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was well tolerated with no serious or severe adverse events, supporting advancement into Phase 2 development for CIDP Menlo Park, Calif., May 14, 2025 – Nuvig Therapeutics, Inc.,…
Menlo Park, Calif., December 5, 2024 – Nuvig Therapeutics, Inc., (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced today the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture…
Redwood City, Calif., February 12, 2024 – Nuvig Therapeutics, Inc., (“Nuvig” or the “Company”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases today announced the first-in-human dosing of NVG-2089, a proprietary product being developed to treat patients with inflammatory myopathies and severe dermatologic autoimmune disease. Nuvig also announced…